Bellicum Pharmaceuticals Valuation
| BLCMDelisted Stock | USD 0.37 0.05 11.90% |
Bellicum Pharmaceuticals seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Bellicum Pharmaceuticals from analyzing the firm fundamentals such as Operating Margin of (19.69) %, return on equity of -1.06, and Shares Outstanding of 9.5 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Bellicum Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Bellicum Pharmaceuticals is based on 3 months time horizon. Increasing Bellicum Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Bellicum pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Bellicum Pharmaceuticals. Since Bellicum Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bellicum Pink Sheet. However, Bellicum Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.37 | Real 0.35 | Hype 0.37 | Naive 0.16 |
The intrinsic value of Bellicum Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bellicum Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Bellicum Pharmaceuticals helps investors to forecast how Bellicum pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bellicum Pharmaceuticals more accurately as focusing exclusively on Bellicum Pharmaceuticals' fundamentals will not take into account other important factors: Bellicum Pharmaceuticals Total Value Analysis
Bellicum Pharmaceuticals is currently forecasted to have valuation of (38.62 M) with market capitalization of 3.52 M, debt of 58 K, and cash on hands of 33.17 M. The negative valuation of Bellicum Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Bellicum Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(38.62 M) | 3.52 M | 58 K | 33.17 M |
Bellicum Pharmaceuticals Investor Information
About 29.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.0. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bellicum Pharmaceuticals recorded a loss per share of 1.57. The entity had 1:10 split on the 6th of February 2020. Based on the key indicators related to Bellicum Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Bellicum Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Bellicum Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Bellicum Pharmaceuticals has an asset utilization ratio of 6.3 percent. This suggests that the Company is making $0.063 for each dollar of assets. An increasing asset utilization means that Bellicum Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Bellicum Pharmaceuticals Ownership Allocation
Bellicum Pharmaceuticals shows 4.19 percent of its outstanding shares held by insiders and 29.31 percent owned by other corporate entities.Bellicum Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 1.5 M. Net Loss for the year was (24.97 M) with loss before overhead, payroll, taxes, and interest of (17.38 M).About Bellicum Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Bellicum Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Bellicum Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Bellicum Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Bellicum Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Bellicum Pharmaceuticals. We calculate exposure to Bellicum Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bellicum Pharmaceuticals's related companies.Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas. Bellicum Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.
8 Steps to conduct Bellicum Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Bellicum Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Bellicum Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Bellicum Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Bellicum Pharmaceuticals' revenue streams: Identify Bellicum Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Bellicum Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Bellicum Pharmaceuticals' growth potential: Evaluate Bellicum Pharmaceuticals' management, business model, and growth potential.
- Determine Bellicum Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Bellicum Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Bellicum Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Bellicum Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 30.8 M | |
| Quarterly Earnings Growth Y O Y | -0.933 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Bellicum Pink Sheet
If you are still planning to invest in Bellicum Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellicum Pharmaceuticals' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |